Background
Methods
Cases and controls
Genotyping
HPV16 serologic testing
Statistical analysis
Results
Demographic variables and risk factors among study subjects
Characteristics | Cases (n = 313) | Controls (n = 314) |
P values | OR (95% CI)* | ||
---|---|---|---|---|---|---|
Number | (%) | Number | (%) | |||
Age (years)
| 0.247 | |||||
<58
| 152 | (48.6) | 167 | (53.2) | 1 | |
≥58
| 161 | (51.4) | 147 | (46.8) | 1.20 (0.88-1.65) | |
Sex
| 0.673 | |||||
Female
| 47 | (15.0) | 51 | (16.2) | 1 | |
Male
| 266 | (85.0) | 263 | (83.8) | 1.10 (0.71-1.69) | |
Tobacco smoking
| <0.001 | |||||
Never
| 92 | (29.4) | 158 | (50.3) | 1 | |
Ever
| 221 | (70.6) | 156 | (49.7) | 2.43 (1.75-3.38) | |
Alcohol drinking
| 0.001 | |||||
Never
| 115 | (36.7) | 156 | (49.7) | 1 | |
Ever
| 198 | (63.3) | 158 | (50.3) | 1.70 (1.24-2.34) | |
HPV status
| ||||||
-
| 143 | (45.7) | 178 | (56.7) | 0.006 | 1 |
+
| 170 | (54.3) | 136 | (43.3) | 1.56 (1.14-2.13) |
Stratified analysis of ESCC risk by HPV16 L1 status
Genotype distribution of susceptibility loci and association with ESCC risk
Susceptibility Loci | Cases (n = 313) | Controls (n = 314) |
P values* | Adjusted OR (95% CI)†
| ||
---|---|---|---|---|---|---|
No. | % | No. | % | |||
rs738722
α
| 0.361 | |||||
CC (Ref.)
| 169 | 54.0 | 187 | 59.6 | 1.00 | |
CT
| 122 | 39.0 | 109 | 34.7 | 1.22 (0.87-1.73) | |
TT
| 22 | 7.0 | 18 | 5.7 | 1.34 (0.68-2.66) | |
Trend test
|
P = 0.242 | |||||
TT + CT
| 144 | 46.0 | 127 | 40.4 | 1.22 (0.88-1.69) | |
rs2074356
β
| 0.011 | |||||
CC (Ref.)
| 196 | 62.6 | 227 | 72.3 | 1.00 | |
TT
| 2 | 0.6 | 5 | 1.6 | 0.61 (0.12-3.22) | |
TC
| 115 | 36.7 | 82 | 26.1 | 1.61 (1.12-2.30) | |
Trend test
|
P = 0.019 | |||||
TT + TC
| 117 | 37.3 | 87 | 27.7 | 1.52 (1.07-2.16) | |
rs2274223
γ
| 0.006 | |||||
AA (Ref.)
| 172 | 55.0 | 209 | 66.6 | 1.00 | |
AG
| 122 | 39.0 | 96 | 30.6 | 1.70 (1.20-2.41) | |
GG
| 19 | 6.1 | 9 | 2.9 | 2.86 (1.22-6.71) | |
Trend test
|
P = 0.001 | |||||
GG + AG
| 141 | 45.1 | 105 | 33.5 | 1.75 (1.25-2.46) |
Interactions of C12orf51 rs2074356 and PLCE1 rs2274223 on the risk of ESCC
Rs2074356 | Rs2274223 | Cases (n = 313) | Controls (n = 314) | AdjustedP value | Adjusted OR (95% CI)* | ||
---|---|---|---|---|---|---|---|
No. | % | No | % | ||||
CC
|
AA
| 109 | 34.8 | 146 | 46.5 | 1 | |
CC
|
GG/AG
| 87 | 27.8 | 81 | 25.8 | 0.024 | 1.60 (1.06-2.42) |
CT/TT
|
AA
| 63 | 20.1 | 63 | 20.1 | 0.211 | 1.33 (0.85-2.08) |
CT/TT
|
GG/AG
| 54 | 17.3 | 24 | 7.6 | <0.001 | 3.31 (1.87-5.83) |
Rs2074356*rs2274223
| 0.002 | 1.26 (1.09-1.45) |
Interactions of HPV16 seropositivity and SNPs at susceptibility loci on the risk of ESCC
HPV16 status | Susceptibility Loci | Cases (n = 313) | Controls (n = 314) | AdjustedP values | Adjusted OR (95% CI)*
| ||
---|---|---|---|---|---|---|---|
No. | % | No. | % | ||||
Rrs738722
| |||||||
Negative
|
CC (Ref.)
| 70 | 22.4 | 106 | 33.8 | 1.00 | |
Negative
|
TT + CT
| 73 | 23.3 | 72 | 22.9 | 0.112 | 1.45 (0.92-2.30) |
Positive
|
CC
| 99 | 31.6 | 81 | 25.8 | 0.002 | 2.00 (1.29-3.10) |
Positive
|
TT + CT
| 71 | 22.7 | 55 | 17.5 | 0.003 | 2.09 (1.29-3.38) |
G*HPV16
| 0.068 | 1.223 (0.99-1.52) | |||||
rsrs2074356
| |||||||
Negative
|
CC (Ref.)
| 87 | 27.8 | 128 | 40.8 | 1.00 | |
Negative
|
TT + TC
| 56 | 17.9 | 50 | 15.9 | 0.054 | 1.61 (0.99-2.62) |
Positive
|
CC
| 109 | 33.9 | 99 | 31.5 | 0.005 | 1.78 (1.19-2.66) |
Positive
|
TT + TC
| 61 | 19.5 | 37 | 11.8 | <0.001 | 2.66 (1.59-4.46) |
G*HPV16
| 0.005 | 1.40 (1.11-1.77) | |||||
rsrs2274223
| |||||||
Negative
|
AA (Ref.)
| 82 | 26.2 | 118 | 37.6 | 1.00 | |
Negative
|
GG + AG
| 61 | 19.5 | 60 | 19.1 | 0.055 | 1.59 (0.99-2.55) |
Positive
|
AA
| 90 | 28.8 | 91 | 29.0 | 0.042 | 1.55 (1.02-2.37) |
Positive
|
GG + AG
| 80 | 25.6 | 45 | 14.3 | <0.001 | 3.17 (1.94-5.17) |
GG*HPV16
| <0.001 | 1.53 (1.23-1.91) |